{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:31:26Z","timestamp":1792812686204,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s41669-025-00612-z","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T15:48:59Z","timestamp":1768924139000},"page":"491-501","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Incremental Disease Burden (Healthcare Costs and Resources) of Duchenne Muscular Dystrophy in the US: A Matched Cohort Analysis"],"prefix":"10.1007","volume":"10","author":[{"given":"Mena","family":"Scavina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nate","family":"Posner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Dorling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Talaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Stachel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Alvir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"issue":"1","key":"612_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0960-8966(91)90039-U","volume":"1","author":"AE Emery","year":"1991","unstructured":"Emery AE. Population frequencies of inherited neuromuscular diseases\u2013a world survey. Neuromuscul Disord. 1991;1(1):19\u201329.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"612_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000512647","volume":"55","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Mann JR, James KA, McDermott S, Conway KM, Paramsothy P, et al. Duchenne and Becker muscular dystrophies\u2019 prevalence in MD starnet surveillance sites: an examination of racial and ethnic differences. Neuroepidemiology. 2021;55(1):47\u201355.","journal-title":"Neuroepidemiology"},{"issue":"1","key":"612_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/mus.23810","volume":"48","author":"JR Mendell","year":"2013","unstructured":"Mendell JR, Lloyd-Puryear M. Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy. Muscle Nerve. 2013;48(1):21\u20136.","journal-title":"Muscle Nerve"},{"issue":"4","key":"612_CR4","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1212\/WNL.0000000000002891","volume":"87","author":"L Bello","year":"2016","unstructured":"Bello L, Morgenroth LP, Gordish-Dressman H, Hoffman EP, McDonald CM, Cirak S, et al. DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study. Neurology. 2016;87(4):401\u20139.","journal-title":"Neurology"},{"issue":"6","key":"612_CR5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1212\/WNL.0000000000000669","volume":"83","author":"E Landfeldt","year":"2014","unstructured":"Landfeldt E, Lindgren P, Bell CF, Schmitt C, Guglieri M, Straub V, et al. The burden of Duchenne muscular dystrophy: an international, cross-sectional study. Neurology. 2014;83(6):529\u201336.","journal-title":"Neurology"},{"issue":"6","key":"612_CR6","first-page":"633","volume":"23","author":"S Thayer","year":"2017","unstructured":"Thayer S, Bell C, McDonald CM. The direct cost of managing a rare disease: assessing medical and pharmacy costs associated with Duchenne muscular dystrophy in the United States. J Manag Care Spec Pharm. 2017;23(6):633\u201341.","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"612_CR7","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1007\/s12325-022-02117-1","volume":"39","author":"J Iff","year":"2022","unstructured":"Iff J, Zhong Y, Gupta D, Paul X, Tuttle E, Henricson E, et al. Disease progression stages and burden in patients with Duchenne muscular dystrophy using administrative claims supplemented by electronic medical records. Adv Ther. 2022;39(6):2906\u201319.","journal-title":"Adv Ther"},{"issue":"3","key":"612_CR8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251\u201367.","journal-title":"Lancet Neurol"},{"issue":"10119","key":"612_CR9","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","volume":"391","author":"CM McDonald","year":"2018","unstructured":"McDonald CM, Henricson EK, Abresch RT, Duong T, Joyce NC, Hu F, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet. 2018;391(10119):451\u201361.","journal-title":"Lancet"},{"issue":"9","key":"612_CR10","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0086","volume":"12","author":"J Iff","year":"2023","unstructured":"Iff J, Zhong Y, Tuttle E, Gupta D, Paul X, Erik H. Real-world evidence of eteplirsen treatment effects in patients with Duchenne muscular dystrophy in the USA. J Comp Eff Res. 2023;12(9):e230086.","journal-title":"J Comp Eff Res"},{"issue":"1","key":"612_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.53094","volume":"7","author":"D Hong","year":"2024","unstructured":"Hong D, Avorn J, Wyss R, Kesselheim AS. Characteristics of patients receiving novel muscular dystrophy drugs in trials vs routine care. JAMA Netw Open. 2024;7(1):e2353094.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"612_CR12","first-page":"1033","volume":"29","author":"R Schrader","year":"2023","unstructured":"Schrader R, Posner N, Dorling P, Senerchia C, Chen Y, Beaverson K, et al. Development and electronic health record validation of an algorithm for identifying patients with Duchenne muscular dystrophy in US administrative claims. J Manag Care Spec Pharm. 2023;29(9):1033\u201344.","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"612_CR13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8.","journal-title":"J Chronic Dis"},{"issue":"1","key":"612_CR14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13023-014-0210-9","volume":"9","author":"O Schreiber-Katz","year":"2014","unstructured":"Schreiber-Katz O, Klug C, Thiele S, Schorling E, Zowe J, Reilich P, et al. Comparative cost of illness analysis and assessment of health care burden of Duchenne and Becker muscular dystrophies in Germany. Orphanet J Rare Dis. 2014;9(1):210.","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"612_CR15","first-page":"1426","volume":"27","author":"AC Klimchak","year":"2021","unstructured":"Klimchak AC, Szabo SM, Qian C, Popoff E, Iannaccone S, Gooch KL. Characterizing demographics, comorbidities, and costs of care among populations with Duchenne muscular dystrophy with Medicaid and commercial coverage. J Manag Care Spec Pharm. 2021;27(10):1426\u201337.","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"612_CR16","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/mus.24965","volume":"53","author":"LJ Teoh","year":"2016","unstructured":"Teoh LJ, Geelhoed EA, Bayley K, Leonard H, Laing NG. Health care utilization and costs for children and adults with Duchenne muscular dystrophy. Muscle Nerve. 2016;53(6):877\u201384.","journal-title":"Muscle Nerve"},{"issue":"1","key":"612_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13023-022-02241-9","volume":"17","author":"SJ Howe","year":"2022","unstructured":"Howe SJ, Lapidus D, Hull M, Yeaw J, Stevenson T, Sampson JB. Healthcare resource utilization, total costs, and comorbidities among patients with myotonic dystrophy using U.S. insurance claims data from 2012 to 2019. Orphanet J Rare Dis. 2022;17(1):79.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"612_CR18","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/mus.27505","volume":"65","author":"KM Conway","year":"2022","unstructured":"Conway KM, Grosse SD, Ouyang L, Street N, Romitti PA. Direct costs of adhering to selected Duchenne muscular dystrophy care considerations: estimates from a midwestern state. Muscle Nerve. 2022;65(5):574\u201380.","journal-title":"Muscle Nerve"}],"updated-by":[{"DOI":"10.1007\/s41669-026-00646-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000}}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00612-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-025-00612-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00612-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T12:57:25Z","timestamp":1779368245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-025-00612-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["612"],"URL":"https:\/\/doi.org\/10.1007\/s41669-025-00612-z","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"14 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised. The following Conflict of Interest statement was added for author Mena Scavina: \"She was also a consultant to Parent Project Muscular Dystrophy (PPMD)\"","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s41669-026-00646-x","URL":"https:\/\/doi.org\/10.1007\/s41669-026-00646-x","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mena Scavina was a paid consultant for Pfizer and had received a grant for her time as a consultant. She was also a consultant to Parent Project Muscular Dystrophy (PPMD). Nathaniel Posner is employed at Pfizer and holds stock ownership. Anna Talaga is a previous employee and stockholder of Pfizer. Jose Alvir is employed at Pfizer and holds stock ownership. The rest of the authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"There is no requirement for review since this study only uses commercially available de-identified secondary data sources and is considered exempt from the requirements for \u201chuman subjects research\u201d in the USA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See\u00a0\n                      \n                      \u00a0for more information.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication (from Patients\/Participants)"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization: Nathaniel Posner, Patricia Dorling, Anna Talaga; Methodology: Mena Scavina, Nathaniel Posner, and Anna Stachel; formal analysis and investigation: Mena Scavina, Nathaniel Posner, Patricia Dorling, Anna Talaga, Anna Stachel, and Jose Alvir; writing\u2014original draft preparation: Mena Scavina, Nathaniel Posner, and Anna Talaga; writing\u2014review and editing: Mena Scavina, Nathaniel Posner, Patricia Dorling, Anna Stachel, and Jose Alvir; funding acquisition: Nathaniel Posner and Anna Talaga; administrative, technical, or logistic support: Anna Talaga; supervision: Nathaniel Posner","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}